Results from 12 weeks of follow-up in a phase I dose-escalating, safety and tolerability study evaluating intravitreal volociximab in combination with ranibizumab for the treatment of neovascular age-related macular degeneration are favorable in showing no dose-limiting toxicity so far, according to one expert.
The chief medical editor reflects on stocks, retirement and careers in research.
The idea to use a nanosecond laser-based treatment to impede the progress of age-related macular degeneration seems to have been fruitful.
Automated structural technologies can detect changes in the optic nerve head and the retinal nerve fiber layer associated with glaucoma before perimetric testing.
Endoscopic cyclophotocoagulation combined with pars plana vitrectomy is a safe and highly effective technique for treating elevated IOP in pseudophakic eyes.
A published study of treatment-na?ve patients with glaucoma prescribed a prostaglandin analogue agent re-affirms that persistence with ocular hypertension therapy is an important problem.
Results of a retrospective study analyzing images acquired by spectral-domain optical coherence tomography show that when compared with healthy control eyes, the subfoveal choroid is thinner in eyes with glaucoma and thicker in eyes with ocular hypertension.
Learn from Benjamin Franklin's wisdom how all lenses are "specialty" lenses in a sense.
Results of a retrospective chart review study show that non-penetrating Schlemm's canaloplasty can be as effective as trabeculectomy with mitomycin-C for providing IOP control in eyes with open-angle glaucoma but may be a potentially safer option because it avoids a bleb.
The experience of having a patient with early glaucoma is not uncommon.
A common sentiment from patients, who are often on a quest to regain youthful eyesight, is "I wish I were young again."
The implantation of multiple trabecular micro-bypass implants in Schlemm's canal following phacoemulsification successfully and significantly reduced IOP for 12 months after implantation as well as the number of medications required to maintain the target IOP.
Simplification of the therapeutic regimen to enable compliance is the primary rationale for using a fixed-combination product in the management of glaucoma, but IOP-lowering efficacy along with safety and tolerability cannot be overlooked.
A portfolio of diagnostic, therapeutic, and data management tools for glaucoma can improve clinical assessment and progression analysis.
Alcon Laboratories announced Sept. 21 that the FDA approved travoprost ophthalmic solution 0.004% formulated with a proprietary ionic-buffered preservative system for first-line treatment to reduce elevated IOP in patients with ocular hypertension or open-angle glaucoma.
The newly expanded $132 million Kellogg Eye Center at the University of Michigan, Ann Arbor, boasts 230,000 square feet of clinical and research space across eight floors that house clinics, six operating rooms, research space, and faculty offices.
Sunwear protects eye health, enhances vision in bright sunlight, and contributes to the bottom line.
Disability from symptoms of dry eye disease among patients using latanoprost 0.005% may be significantly improved by switching to a benzalkonium chloride-free formulation of travoprost 0.004%.
Alpha adrenoceptor agonist therapy using brimonidine tartrate 0.1% with a preservative has a wide spectrum of uses in the management of ocular hypertension and glaucoma.
A dexamethasone 0.7 mg intravitreal implant now is approved for treatment of non-infectious uveitis affecting the posterior segment of the eye.
Letter addresses 2010 Ophthalmology Times Best Programs survey.
Understanding of the physiology of aqueous outflow resistance through the conventional outflow pathway should help to identify new therapeutic targets for IOP lowering and may lead to novel modalities for glaucoma therapy, according to one expert.
Remembering the rules of the road can help clinic managers and administrators who want to keep their practice on the road with minimal breakdowns.
Selective laser trabeculoplasty is a safe and effective first-line procedure for glaucoma that works as well as the strongest anti-glaucoma medication.
Under the theme of "Visionary Genomics," researchers and clinicians will gather at the 2011 annual meeting of the Association for Research in Vision and Ophthalmology in May in Fort Lauderdale, FL, to explore how genomic technology is leading to new understanding of vision health, disease and treatment.
Optos has entered into an agreement with Accutome Inc. to distribute three of its medical devices in North America and targeted European markets starting in November.
A potential advance in the fight against blindness is the development of an experimental oral synthetic retinoid compound to treat two subtypes of Leber's congenital amaurosis.
Compared with standard 2.75-mm coaxial small-incision cataract surgery, eyes treated with biaxial microincision cataract surgery sustained less trauma due to lower amounts of energy and faster visual rehabilitation.
Findings from bench model studies measuring higher-order aberrations and near, intermediate, and distance image quality of presbyopia-correcting IOLs provide further insight on the clinical performance of the available implants.
Two distinct regions of the cornea have key anatomic, physiologic, and pathologic differences.
